DCT Takes Center Stage at DIA 2022 With new Tufts ROI
No items found.
Save the Date!
On June 19, 2022, DIA’s Global Annual Meeting returned to Chicago, bringing together industry clinicians, regulators, scientists, academics, and more to discuss the biggest challenges facing life sciences today.
While DIA 2022 officially provided four days' worth of content spanning over 13 talk tracks and hundreds of speakers, our team had three major takeaways from this year’s event.
The ascent of decentralized clinical trials continues with promising new ROI analysis
As McKinsey noted in their June 2021 report “No place like home? Stepping up the decentralization of clinical trials,” the DCT capabilities of our industry are rapidly expanding. Nowhere was this more evident than at DIA 2022, with the recently released Tufts CSDD analysis spearheading the conference’s focus.
On Monday, Kenneth Getz (Executive Director/Professor, Tufts CSDD; Founder/Board Chair, CISCRP, Tufts University School of Medicine) and Pamela Tenaerts (Chief Scientific Officer, Medable) led attendees through their findings from the jointly authored paper.
The paper is the industry’s first analysis of the impact of decentralized trials and showcases how pharmaceutical companies can generate a 5x return on investment (ROI) over time in Phase 2 clinical trials, and a 13x ROI in Phase 3 trials.
For an hour, Ken and Pam explained how decentralized clinical trials reduce clinical trial cycle times, lower screen failure rates, and decrease the number of protocol amendments in order to generate their value.
As Pam noted on her LinkedIn post after presenting - “Money spent on #DCTs is well spent with an #ROI of 5x for the total phase 2 and 13x for phase 3.
Points to remember
The model is based on real data. Protocol performance and contract value data
It is a conservative base case
We are committed to more data to refine and rerun the model
Of course, We do #DCTs for more than the ROI, to make trials easier for people to participate, to reflect the population living with the condition under study, and to get more and better evidence and reliable data.
I’ve been working in trials for 30 years. Those better trials have never felt closer than before, especially with the movement to #communitybased clinical trials and #qualitybydesign.”